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Abstract: Background: Contrasting data are available in the literature regarding the superiority of
percutaneous microwave ablation (MWA) or radiofrequency ablation (RFA) in very early or early
(BCLA 0 or A) hepatocellular carcinoma (HCC). Aims: The primary outcome was to compare the
efficacy of RFA and MWA in achieving complete response in cirrhotic patients with early and very
early HCC. The secondary outcomes were to evaluate the overall survival and the recurrence rate.
Methods: A retrospective, observational, single-center study was performed. Inclusion criteria were
liver cirrhosis, new diagnosis of a single node of HCC measuring a maximum of 50 mm or up to
three nodules with diameter up to 35 mm, treatment with RFA or MWA. Radiological response
was evaluated with multiphasic contrast-enhanced Computed Tomography or Magnetic Resonance
Imaging at 5–7 weeks after thermal ablation. Complete response was defined when no vital tissue
was detected after treatment. Results: Overall, 251 HCC patients were included in this study; 81
patients were treated with MWA and 170 with RFA. The complete response rate was similar in MWA
and RFA groups (out of 331 nodules, 87.5% (91/104) were treated with MWA and 84.2% (186/221)
were treated with RFA, p = 0.504). Interestingly, a subanalysis demonstrated that for 21–35 mm
nodules, the probability to achieve a complete response using MWA was almost 5 times higher than
for RFA (OR = 4.88, 95% CI 1.37–17.31, p = 0.014). Moreover, recurrence rate in 21–35 mm nodules
was higher with RFA with respect to MWA (31.9% versus 13.5%, p = 0.019). Overall survival was
80.4% (45/56) when treated with MWA and 62.2% (56/90) when treated with RFA (p = 0.027). No
significant difference was observed between MWA and RFA treatment in the 15–20 mm nodules
group. Conclusion: This study showed that MWA is more efficient than RFA in achieving complete
response in HCC nodules with 21 to 35 mm diameter.
Keywords: microwave ablation; hepatocellular carcinoma; radiofrequency ablation; locoregional
therapy; necrosis; percutaneous techniques; survival
1. Introduction
Hepatocellular carcinoma (HCC) represents about 90% of primary liver cancers. Cur-
rently, HCC is the seventh most common cancer and the second for mortality in the world,
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and its incidence and mortality rates are expected to increase in the upcoming decades [1,2].
HCC therapy is complex and involves several strategies depending on the stage (resection,
percutaneous techniques, liver transplantation, chemoembolization, radioembolization, ra-
diotherapy, target therapy), and multiple options may be available to the same patient [3,4].
According to the Barcelona Clinic Liver Cancer (BCLC) staging system, radiofrequency
ablation (RFA) and microwave ablation (MWA) are widely employed treatments for very
early (BCLC 0) and early (BCLC A) HCC [5,6]. The assessment of response to locoregional
HCC therapy is evaluated with multiphasic contrast-enhanced Computed Tomography
(CT) or Magnetic Resonance Imaging (MRI), relying on mRECIST criteria [7].
Contrasting data are available on the efficiency of RFA and MWA. In clinical practice,
HCC nodes with a diameter from 15 to 35 cm are treated indifferently with RFA or MWA,
depending on the choice of the clinician. Several studies comparing RFA with MWA
indicated a similar efficacy between the two percutaneous techniques, while one study
showed possible superiority of MWA in HCC with larger nodules [8].
RFA is based on generation of a current (370 to 505 kHz) through an electrode tip
inserted into the tumoral node that induces local heat (55 to 95 ◦C) and causes necrosis.
The heat propagates in a centrifugal direction and the temperature decreases. This is the
cause of the decrease of its efficacy in HCC nodes larger than 20 mm. MWA is a thermal
technique that creates an electromagnetic field around a monopolar electrode, inducing
homogeneous heating and necrosis. MWA offers several advantages over the other forms
of thermal ablation such as: inducing larger volumes of necrosis; reaching faster ablation
rates; increasing the sphericity of the necrosis area due to development; and application of
high-powered antennas and new powerful generators [9–11].
The aim of the study is to compare the efficacy of RFA and MWA in achieving complete
response in cirrhotic patients with early and very early HCC. Moreover, the overall survival,
the recurrence rate in patients treated with RFA and MWA, and the variables that may
influence the outcomes were evaluated.
2. Materials and Methods
2.1. Patients
This retrospective observational study included all consecutive patients with cirrhosis
and first diagnosis of HCC treated with percutaneous thermal ablation by RFA and MWA at
the Gastroenterology and Hepatology Unit, “Città della Salute e della Scienza” University-
Hospital, Turin, Italy, from January 2013 to May 2019. Diagnosis of HCC and allocation
treatment followed BCLC and EASL guidelines [10,12].
Inclusion criteria were the following: patients with liver cirrhosis (Child Pugh score
A or B), new diagnosis of a single node of HCC measuring a maximum of 50 mm or up
to three nodules with diameter up to 35 mm, treated with percutaneous ultrasound (US)-
guided RFA or MWA. The choice between RFA or MWA depended on local availability
and on the preference of the operator. All the procedures were performed by 3 highly
experienced hepatologists with more than 6 years of US-guided thermal ablation activity.
Other treatments or combination therapies were excluded. Demographic, clinical, and
radiological data were prospectively collected at the time of intervention, and patients
were subsequently followed up and staged at our hospital.
Data regarding aetiology of cirrhosis, hepatic function (Child Pugh-score), age, sex,
body mass index (BMI), alcohol and smoking habits, number of lesions and their radiologi-
cal characteristics were collected. Specifically, HCC nodules were examined for maximum
diameter of lesion in cases of a single tumor, sum of sizes in cases of multiple lesions (sum
of diameters-SOD), number of lesions, complex position (perivascular, subdiaphragmatic,
pericholecystic, subcapsular lesions) and ultrasound visibility (poor or good visibility).
2.2. HCC Nodules: Evaluation of the Tumor Response
Only well-delineated, arterially enhancing lesions that could be measured and selected
as target lesions for EASL criteria [10] at pretherapy multiphasic contrast-enhanced CT or
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MRI were included in the study. Radiological response was evaluated following EASL
criteria with multiphasic contrast-enhanced CT or MRI at 5–7 weeks after first treatment.
Further, patients were followed by specialist abdominal US with or without contrast
enhancement every 4 months, and CT or MRI yearly, following EASL guidelines [10]. End
of follow-up was considered at study end (15 May 2019) or when death occurred or upon
orthotopic liver transplantation. All patients signed an informed consent for the procedure
and for data collection in respect of their privacy following the Ethical Committee approval
(Italian Legislative Decree No. 196 dated 30 June 2003). Complete response is defined as
the disappearance of any intratumoral arterial enhancement; residual viable tumor tissue
is defined as the arterially enhancing tissue within the treated HCC, and it is measured to
assess treatment response. Recurrence is defined, after a complete response, as the presence
of vital tumor occurring locally.
2.3. Statistical Analysis
Baseline characteristics of all patients included in the analysis are summarized using
median and interquartile range (IQR), and percentages and frequencies (n, %). Between-
group differences in sociodemographic and clinical characteristics at HCC diagnosis were
evaluated by the Mann–Whitney U test for continuous variables and the Chi-square test
or Fisher’s exact test for categorical variables. Complete radiological response in the
subpopulation of nodules with a diameter from 15 to 35 mm was evaluated using a logistic
regression model, overall and between diameter groups (15–20 mm vs. 21–35 mm). Crude
and adjusted Odds Ratios (ORs) and their 95% confidence intervals (95% CI) were reported.
Multivariable models included all factors known to have a predictive role on response
(nodules position and visibility, Child Pugh class, number of lesions, and diameter of
lesions).
To describe the timing of recurrence, the cumulative incidence of recurrence was
estimated. Statistical significance (p < 0.05) of differences in the cumulative incidence of
recurrence between groups (i.e., by treatment, diameter group, position, visibility) was
tested using the log-rank test for homogeneity. The observation period for time to recur-
rence started on the day of thermoablation treatment until the date of recurrence diagnosis
(failures), or the last follow-up visit (censoring). Patients who underwent orthotopic liver
transplantation were censored at the time of intervention. In this analysis, death was
considered as a competing event. We estimated Subdistributional Hazard Ratios (SHR)
in a semiparametric model according to Fine and Gray to evaluate possible predictors of
recurrence and plotted the cumulative incidence function. The overall survival, estimated
with the Kaplan–Meier method, was defined as the time from thermoablation to death
by any cause; patients alive were censored on the date of the last follow-up. Orthotopic
liver transplantation was considered a time-dependent variable in the model. Potential
prognostic variables were evaluated as predictors of survival by the Cox proportional
hazard model to estimate the crude and the multivariable-adjusted Hazard Ratios (HRs)
with 95% Confidence Intervals (CIs) and to evaluate possible predictors of survival. The
proportional hazard assumption was also verified by graphical checks and formal tests
based on Schoenfeld residuals. The variables that a priori were considered to have clinical
relevance, such as nodule position, diameter, visibility, and number of lesions present, were
included in the multivariable model. The analysis was performed by Stata 15.1 software
(StataCorp LP, College Station, TX, USA).
3. Results
3.1. Patients
Overall, 251 HCC patients with 331 nodules were included in this study. Median age
was 64 years old (IQR 56–73), with 87% in Child Pugh class A and 13% in Child Pugh class
B at the moment of thermal ablation. A total of 81 patients were treated with MWA and 170
with RFA; the two groups of patients were homogeneous in terms of demographical and
clinical features. However, the median time of follow-up was 2.48 years (IQR 1.32–3.81)
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and was significantly longer in patients treated with RFA compared with those treated
with MWA: 2.94 (IQR 1.61–4.25) vs. 1.66 (0.86–3.20), p < 0.001. Patient details are described
in Table 1.






n = 170 p Value
Age, median years (IQR) 67 (57–73) 63 (56–72) 0.584
Sex, M/F (M%) 62/19 (76.5) 118/52 (69.4) 0.294
BMI, median Kg/m2 (IQR) 25.2 (22.5–28.1) 25.7 (23.4–28.3) 0.618
Smoke habit, n (%)
• Ex smokers 32 (39.5) 49 (28.8)
0.262• Active smokers 25 (30.9) 59 (34.7)
Alcohol intake, n (%)
• Ex alcoholic 45 (55.6) 80 (47.1)
0.407• Active alcoholics 12 (14.8) 27 (15.5)
Child-Pugh Score, n (%)
• A 71 (87.7) 148 (87.1)
1.000• B 10 (12.3) 22 (12.9)
Albumin, median g/dL (IQR) 4 (3.5–4.3) 3.7 (3.3–4.2) <0.050
AFP, median ng/mL (IQR) 6.3 (3.6–25.2) 9.5 (4–23) 0.657
Ascites, n (%) 9 (11.1) 22 (12.9) 0.838
Number of patients with 1 or 2 or 3
treated nodules, n (%)
• 1 nodule 62 (76.5) 127 (74.7)
0.511• 2 nodules 13 (16) 35 (20.6)
• 3 nodules 6 (7.4) 8 (4.7)
Follow up time, median years (IQR) 1.7 (0.9–3.2) 2.9 (1.6–4.3) <0.001
LT, n (%) 18 (22.2) 36 (21.2) 0.870
MWA = microwave ablation; RFA = radiofrequency ablation; IQR = interquartile range; M = male; F
= female; BMI = body mass index; AFP = alfa-fetoprotein; LT = liver transplantation.
Overall, the 331 HCC nodules included had a median of maximum diameter of 21 mm
(IQR 16–28). At inclusion time, 75% (189) of cases had a single HCC nodule, 19% (48) had
two nodules, and 5.6% (14) had 3 nodules; 106 nodules (32%) were treated with MWA and
225 (68%) with RFA. The nodules treated with MWA were significantly larger than those
treated with RFA, with a median diameter of 29 mm (IQR 20–35 mm) vs. 20 mm (IQR
15–25 mm), respectively, p < 0.001. The median of maximum diameter and of SOD, in the
case of multiple lesions for each patient, was 27 mm (IQR 20–35): 33 mm (IQR 27–45) in the
MWA group and 25 mm (19–31) in the RFA group, respectively.
Features of all included nodules treated with RFA and MWA are reported in Table 2.
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n = 225 p Value
Diameter, median mm (IQR) 29 (20–35) 20 (15–25) <0.001
Diameter
• ≤14 mm, n (%) 5 (4.7) 48 (21.3)
<0.001
• 15–20 mm, n (%) 22 (20.8) 81 (36)
• 21–35 mm, n (%) 56 (52.8) 91 (40.4)
• ≥36 mm, n (%) 23 (21.7) 5 (2.2)
Infiltrative nodules, n (%) 4 (3.8) 3 (1.3) 0.384
Complex position, n (%) 23 (21.7) 56 (24.9) 0.582
Poor US visibility, n (%) 8 (7.5) 34 (15.1) 0.075
MWA = microwave ablation; RFA = radiofrequency ablation; US = ultrasonography.
3.2. Radiological Response and Recurrence
Complete radiological response was achieved in 83.7% (277/331) of nodules treated
with any thermoablation therapy. The rate of complete response was dependent on nodule
diameter, and the risk of recurrence was related to the dimension of the single nodule
treated as shown in Figure 1.
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Figure 1. Rate of complete necrosis (left axis) and recurrence rate (right axis) in 331 hepatocellular carcinoma (HCC) nodules
treated with any percutaneous thermal ablation, p < 0.05 (test for trend).
The complete response rate was similar in MWA and RFA (87.5%, 91/104 of nodules
treated with MWA and 84.1%, 186/221 of nodules treated with RFA, respectively, p = 0.504).
Six patients were missing: four patients were lost to follow-up, and two patients under-
went liver transplantation three and 20 days after ablation). The cumulative incidence of
recurrence in the whole population was similar in the t o groups of treatment. In fact,
the cumulative incidence of recurrence at 6, 12 and 18 months was, respectively, 2.5%,
8.8% and 14% in the MWA group, and 1.8%, 8.9% and 14.4% in the RFA group (p > 0.05).
At multivariable nalysis, the cumulative inc d nce of re urrenc was influenced by the
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maximum diameter of the HCC nodules (SHR 1.04, 95%CI 1.00–1.08, p = 0.042) and was
not related to type of therapy and other nodule features such as position and US visibility.
In case of recurrence, the tumor was thermal ablated again if possible or treated with
other techniques such as trans arterial chemoembolization or stereotactic radiotherapy, if
indicated, or patient underwent liver transplantation (data not shown).
3.3. Sub-Analysis on Nodules with Diameter between 15 and 35 mm
Considering that very big nodules (larger than 35 mm) were treated primarily with
MWA and small nodules (inferior to 15 mm) with RFA, as shown in Table 2, in order to
make the two groups of therapy more comparable, we performed a subanalysis on 250
HCC nodules with a diameter of 15 to 35 mm. A total of 78 nodules (31%) were treated
with MWA and 172 (69%) with RFA. Nodules treated with MWA were significantly larger
(median diameter of 25 mm (IQR 20–30 mm)) compared to those treated with RFA (mean
diameter of 21 mm (IQR 18–25), p < 0.001).
3.4. Complete Response in Nodules with Diameter between 15 and 35 mm
Complete response was achieved with thermoablation in 84.1% (207/246) of nodules
(in four cases the data were not available: three patients were lost to follow-up, and
one patient underwent liver transplantation three days after ablation). MWA achieved a
complete response in a higher rate of HCC patients with respect to RFA: 92.2% (71/77) of
nodules vs. 80.5% (136/169), respectively, p = 0.02, and, in particular, in nodules with a
diameter of 21–35 mm group (p = 0.007) (Figure 2).
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Figure 2. Complete response in nodules 15–35 mm treated with RFA and MWA.
Following the logistic model, 15–35 mm nodules treated with MWA had 3.26 times
higher probability of achieving complete necrosis (95% CI 1.04–10.2, p = 0.042) than RFA,
independently of the nodule position, visibility, maximum diameter, and Child Pugh class.
Further analysis was performed on two subgroups of nodules based on diameter (15–
20 mm and 21–35 mm), homogeneity in terms of type of therapy, number of lesions for each
patient, complex position (perivascular, subdiaphragmatic, pericholecystic, subcapsular
lesions), US visibility and infiltrative US pattern (p = 0.500) as shown in Supplementary
Table S1.
Taking into account the small 15–20 mm nodules, there was no difference in achieving
complete response between MWA and RFA (OR = 1.37, 95%CI 0.36–5.19, p = 0.641), while
for bigger 21–35 mm nodules, the probability to achieve a complete response using MWA
was almost five times higher than RFA (OR = 4.88, 95% CI 1.37–17.31, p = 0.014).
3.5. Recurrence Rate in Nodules with Diameter between 15 and 35 mm
In the HCC nodules with a dia eter of 15 to 35 mm, the mean recurrence rate after
complete response was 22.2% (46/207): 14.1% (10/71) in nodules treated with MWA and
26.5% (36/136) in those treated with RFA (p = 0.04). For 15–20 mm nodules, the recurrence
rate was similar in the MWA and RFA treatment groups (15.8%, 3/19 vs 20.9%, 14/67,
respectively, p = 0.62), while for bigger 21–35 mm nodules, the recurrence rate was 13.5%
(7/52) in nodules treated with MWA and 31.9% (22/69) in those treated with RFA (p =
0.019). At multivariate analysis, an increasing trend of recurrence risk was observed for
21–35 mm nodules treated with RFA (OR 2.57, 95% CI 0.95–6.94, p = 0.062) compared to
15–20 mm nodules, while the recurrence rate was independent of other HCC features such
as type of therapy, position and US visibility.
3.6. Overall Survival
Death occurred in 58 out of 251 (23%) patients. At multivariate analysis, overall
survival was related to the Child Pugh A vs. B score (HR = 3.46, 95%CI 1.68–7.13, p = 0.001),
and to the SOD (HR = 1.04, 95%CI 1.01–1.07, p = 0.005). Patients who achieved complete
response after thermoablation showed increased overall survival compared to patients with
persistence of vital tissue (p = 0.043, see Figure 3A). The mortality risk between patients
treated with RFA (N = 15, 18.5%) and MWA (N = 43, 25.3%) was similar (HR = 0.97, 95%CI
0.50–1.89, p = 0.938). In Figure 3B, the overall survival probability of patients in the two
groups of treatment is reported.
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3.7. Overall Survival in Nodules with Diameter between 15 and 35 mm
Overall, in HCC nodules with a diameter of 15 to 35 mm, the mean overall survival
was 73.5% (183/249) (in one case the data were not available): 83.3% (65/78) in nodules
treated with MWA and 69% (118/171) in those treate with RFA (p = 0.02). In small
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15–20 mm nodules, the overall survival was 90.9% (20/22) in nodules treated with MWA
and 76.5% (62/81) in those treated with RFA (p = 0.23), while for bigger 21–35 mm nodules,
the overall survival was 80.4% (45/56) in nodules treated with MWA and 62.2% (56/90) in
those treated with RFA (p = 0.027).
4. Discussion
In the present study, we compared the efficacy of percutaneous treatment with RFA
and MWA as a curative purpose in patients with early and very early HCC. Complete
necrosis of tumor tissue was achieved in 84% of nodules without significant differences
between MWA and RFA when all HCC nodules up to 50 mm were considered. However,
in a subgroup of nodules with a diameter of 21 to 35 mm, MWA was superior in achieving
complete response compared to RFA (p = 0.007). Considering 15–35 mm HCC nodules,
those treated with MWA had a higher probability of obtaining a complete necrosis than RFA,
independently of the nodule position, visibility, and Child Pugh class. Recurrence rate was
lower for MWA with respect to RFA when considering nodules with a diameter of 21 to 35
mm: the recurrence rate was 13.5% in nodules treated with MWA and 31.9% in those treated
with RFA. Overall survival depended on the efficacy of treatment (complete response vs.
persistent of vital tissue), liver function (Child Pugh A vs. B), and liver transplantation
after treatment. Taking into account 21–35 mm nodules, the overall survival was 80.4% in
nodules treated with MWA and 62.2% in those treated with RFA. Overall, these results show
that MWA achieved superior complete response in nodules larger than 21 mm compared
to RFA in HCC patients.
Several studies have compared modern MWA and RFA techniques with contrasting
results. Qian et al. found no difference between MWA and RFA in long-term progression
in nodules less than 3 cm in diameter [13]. Potretzke et al. found a 2-fold increased
risk of long-term progression after RFA with respect to MWA: HCC greater than 3 cm in
diameter showed the greatest difference in progression risk between MWA and RFA [14].
A recent study published by Bouda et al. found a higher efficacy of MWA compared
to RFA ablation in 149 patients with naive HCC at very early or early stage in terms of
local tumor progression, but they did not evaluate overall survival [15]. On the other
hand, the study of McDevitt et al. showed no difference in the risk of primary failure or
local progression between RFA and MWA in 136 patients. However, the authors did not
perform a subanalysis in the two groups according to diameter measurement (15–20 mm
and 21–35 mm) [16].
Considering reviews and meta-analyses, no differences in local recurrence for up to
five years after treatment were found comparing MWA and RFA, and MWA is recom-
mended only for lesions >3 cm [8,17–20]. A possible explanation for the higher complete
response rate with MWA found in the 21–35 mm group in comparison with the 15–20 mm
group in our study could be that MWA antenna can achieve continuous and faster heating,
thus generating a larger area of ablation than RFA [21,22]
This study has some limitations, principally due to the retrospective design (despite
the fact that demographic, clinical and radiological data were prospectively collected at
the moment of intervention and periodically revised to avoid missing data), single-center
study, lack of data about complications related to the procedures, and the nonrandomized
treatment allocation. All consecutive 251 patients with cirrhosis and first diagnosis of HCC
treated with thermal ablation at our department were included to avoid biases in selection.
The choice for MWA or RFA was taken by the single operator based on personal experience,
that is, small nodules were preferably treated with RFA while MWA was preferred for
bigger or numerous nodules. RFA was performed by a multiple-hooked needle and was
preferred in cases of unstable position into the liver. MWA was performed with a single-
hook needle and conferred a bigger necrotic area in shorter time and was thus chosen
for bigger HCC or multiple nodules. However, the cost of the MWA needle was higher
compared to RFA (data not shown); this aspect lightly influenced in the first months of
the study the choice of thermal ablation type, favoring RFA. These data explain the longer
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period of follow-up in patients treated with RFA compared to MWA, but did not affect the
results on effectiveness of therapy. These are the main reasons for choosing one treatment
or the other one. In order to compare data, further analysis was performed on 250 nodules
with a diameter of 15 to 35 mm. In this subgroup, the treatment allocation was comparable,
and patients were similar in terms of clinical features, number, and ultrasound features of
the HCC. Our data showed that MWA was superior to RFA in obtaining a complete necrosis
as well as overall survival in 21–35 mm HCC nodules, while no significant difference was
observed for smaller nodules. Moreover, overall survival was higher in patients achieving
complete necrosis independent of the type of therapy. The results of our study could direct
clinicians to choose MWA over RFA in HCC nodes with a diameter of 21 to 35 mm, and
this can therefore improve the standard therapeutic approach to HCC therapy.
In conclusion, our study shows that MWA is preferable to RFA in achieving complete
response, lower recurrence rate, and higher overall survival rate in HCC nodules with a
diameter from 21 to 35 mm: in early, but not in very early HCC, MWA was superior to
RFA.
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9/28/2/101/s1, Supplementary Table S1. Features of 250 HCC nodules with diameter from 15 to
35 mm.
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